Gene therapies for the cats and dogs you love? Penn-partnered Scout Bio just raised $20M to make it a reality
The gene therapy revolution that’s been sweeping through biotech isn’t just about humans anymore. A Penn-partnered biotech called Scout Bio has just picked up a $20 million round to step up its work on once-and-done therapies for common pet ailments.
Co-founded by legendary gene therapy pioneer and Penn investigator James Wilson, Scout is using some familiar AAV tech to go after diseases like chronic kidney disease, chronic pain and the inflammatory skin condition atopic dermatitis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.